Loading...

Recombinant Human M-CSF (carrier-free)

Pricing & Availability
Regulatory Status
RUO
Other Names
CSF1, CSF-1, MCSF
Ave. Rating
Submit a Review
Product Citations
publications
M-CSF_Human_021512
M-NFS-60 cell proliferation induced by human M-CSF.
  • M-CSF_Human_021512
    M-NFS-60 cell proliferation induced by human M-CSF.
  • Recombinant_Human_MCSF_CF_012022
    Recombinant human M-CSF induces the proliferation of mouse M-NFS60 cell line in a dose dependent manner. BioLegend’s protein was compared side-by-side to the leading competitor’s equivalent product.
Cat # Size Price Quantity Check Availability Save
574808 500 µg 1407€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
574802 10 µg 90€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
574804 25 µg 165€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
574806 100 µg 516€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

M-CSF was first characterized as a glycoprotein that induces monocyte and macrophage colony formation from precursors in murine bone marrow cultures. M-CSF is constitutively present at biologically active concentrations in human serum. It binds CD14+ monocytes and promotes the survival/proliferation of human peripheral blood monocytes. In addition, M-CSF enhances inducible monocyte functions including phagocytic activity, microbial killing, cytotoxicity for tumor cells as well as synthesis of inflammatory cytokines such as IL-1, TNFα, and INFγ in monocytes. M-CSF induces RANKL production in mature human osteoclasts; consequently, M-CSF is a potent stimulator of mature osteoclast resorbing activity. Also, M-CSF induces VEGF in human monocytes in human tumors; high levels of M-CSF, mononuclear phagocytes, and VEGF are associated with poor prognosis in patients with cancer. High levels of M-CSF have been associated with different pathologies such as pulmonary fibrosis and atherosclerosis. M-CSF binds to its receptor M-CSFR, and this receptor is shared by a second ligand, IL-34. Human M-CSF and IL-34 exhibit cross-species specificity – both bind to human and mouse M-CSF receptors.

Product Details
Technical Data Sheet (pdf)

Product Details

Source
Human M-CSF, amino acids Glu33-Ser190 (Accession# NM_172212.2) was expressed in 293E cells.
Molecular Mass
The 179 amino acid recombinant protein has a predicted molecular mass of approximately 20.6 kD. The DTT-reduced and non-reduced protein migrate at approximately 25- 35 kD and 55-70 kD respectively by SDS-PAGE. The N-terminal contains a His9-(SGGG)2-IEGR-tag.
Purity
>98%, as determined by Coomassie stained SDS-PAGE.
Formulation
0.22 µm filtered protein solution is in PBS.
Endotoxin Level
Less than 0.01 ng per µg cytokine as determined by the LAL method.
Concentration
10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity
ED50 =0.5 - 2 ng/ml, corresponding to a specific activity of 0.5 - 2 x 106 units/mg, as determined by M-NFS60 cell proliferation induced by human M-CSF in a dose dependent manner.
Application

Bioassay
Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Application References

(PubMed link indicates BioLegend citation)
  1. Lou J, et al. 2014. J Cell Sci. 127:5228. PubMed
Product Citations
  1. Mirji G, et al. 2022. Sci Immunol. 7:eabn0704. PubMed
  2. Hong Y, et al. 2023. iScience. 26:106267. PubMed
  3. Xiang J, et al. 2022. J Virol. 96:e0005722. PubMed
  4. Nilsson A, et al. 2022. Nat Commun. 13:3069. PubMed
  5. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  6. Goel PN, et al. 2019. Biochem Biophys Res Commun. 515:538. PubMed
  7. Nenasheva T, et al. 2020. Front Immunol. 1.163888889. PubMed
  8. Sandstrom TS, et al. 2021. J Virol. 95:. PubMed
  9. Chen X, et al. 2021. Theranostics. 11:3392. PubMed
  10. Cassetta L et al. 2019. Cancer Cell. 35(4):588-602 . PubMed
  11. Cordido A, et al. 2021. J Am Soc Nephrol. 32:1913. PubMed
  12. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  13. Trapecar M, et al. 2021. Sci Adv. 7:00. PubMed
  14. Anantpadma M, et al. 2016. Antimicrob Agents Chemother. 60: 4471 - 4481. PubMed
  15. Yamada KJ, et al. 2020. PLoS Pathog. 16:e1008354. PubMed
  16. Thi Tran U, et al. 2019. Commun Biol. 2:2. PubMed
  17. Zhai K, et al. 2021. Nat Cancer. 2:1136. PubMed
  18. Lin H, et al. 2020. Small. 16:e2002194. PubMed
  19. Heath O, et al. 2021. Cancer Immunol Res. 9:665. PubMed
  20. Yamaguchi Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  21. Dahal S, et al. 2022. Retrovirology. 19:18. PubMed
  22. Brasil da Costa FH, et al. 2020. PLoS One. 15:e0230354. PubMed
  23. Lu Y, et al. 2020. Immunity. 52:782. PubMed
  24. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  25. Heim CE, et al. 2020. Nature Microbiology. 5(10):1271-1284. PubMed
  26. Miyamoto T, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  27. Virtakoivu R, et al. 2021. Clin Cancer Res. 27:4205. PubMed
  28. Lou J, et al. 2014. J Cell Sci. 127:5228. PubMed
  29. Rexach JE, et al. 2020. Cell Rep. 33:108398. PubMed
  30. Kuniholm J, et al. 2021. PLoS Pathog. 17:e1009982. PubMed
  31. Nijaguna M, et al. 2015. J Biol Chem. 290: 23401-23415. PubMed
  32. Lecker LSM, et al. 2021. Cancer Res. 81:5706. PubMed
  33. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed

Antigen Details

Structure
Disulfide-linked glycosylated homodimer
Interaction
Monocytes, macrophages, mononuclear phagocyte precursors, microglia, proliferating smooth muscle cells, umbilical vein endothelial cells, and breast cancer cell lines.
Ligand/Receptor
M-CSFR or CSF1R (CD115)
Cell Type
Embryonic Stem Cells, Hematopoietic stem and progenitors
Biology Area
Cell Biology, Cell Proliferation and Viability, Immunology, Stem Cells
Molecular Family
Cytokines/Chemokines, Growth Factors
Antigen References

1. Kawasaki ES, et al. 1985. Science 230:291.
2. Wei S, et al. 2010. J. Leukoc. Biol. 88:495.
3. Hodge JM, et al. 2011. PloS One 6:e21462.
4. Morandi A, et al. 2011. PloS One 6:e27450.
5. Erblich B, et al. 2011. PloS One 6:e26317.
6. MacDonald KP, et al. 2010. Blood 116:3955.

Gene ID
1435 View all products for this Gene ID
UniProt
View information about M-CSF on UniProt.org

Related FAQs

Why choose BioLegend recombinant proteins?

     • Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
     • Greater than 95% Purity or higher, tested on every lot of product.
     • 100% Satisfaction Guarantee for quality performance, stability, and consistency.
     • Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
     • Bulk and customization available. Contact us.
     • Learn more about our Recombinant Proteins.

How does the activity of your recombinant proteins compare to competitors?

We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!

What is the specific activity or ED50 of my recombinant protein?

The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.

Have your recombinants been tested for stability?

Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.

Does specific activity of a recombinant protein vary between lots?

Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.

How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?

Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)

Go To Top Version: 5    Revision Date: 09/27/2017

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account